New dosing strategy aims to reduce dangerous side effects of stem cell transplants

NCT ID NCT06265584

First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 30 times

Summary

This study tests a two-step method of giving an anti-rejection drug (ATG) along with standard medications to prevent severe graft-versus-host disease (GVHD) in people with blood cancers receiving a stem cell transplant. About 56 adults aged 18-75 will participate. The goal is to see if this approach improves survival without severe GVHD or cancer relapse one year after transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35294, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.